Compare TRN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRN | ADPT |
|---|---|---|
| Founded | 1933 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 1994 | 2019 |
| Metric | TRN | ADPT |
|---|---|---|
| Price | $31.36 | $14.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $34.00 | $17.78 |
| AVG Volume (30 Days) | 507.2K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | ★ 85.98 | 63.89 |
| EPS | ★ 3.05 | N/A |
| Revenue | ★ $2,156,900,000.00 | $276,976,000.00 |
| Revenue This Year | $1.91 | $3.98 |
| Revenue Next Year | $15.61 | $22.72 |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $22.38 | $7.16 |
| 52 Week High | $35.62 | $20.76 |
| Indicator | TRN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 48.30 |
| Support Level | $30.63 | $12.22 |
| Resistance Level | $35.33 | $15.38 |
| Average True Range (ATR) | 0.86 | 0.77 |
| MACD | -0.24 | 0.04 |
| Stochastic Oscillator | 17.21 | 58.78 |
Trinity Industries Inc sells and leases railroad products and railcar maintenance services in North America. The company operates under the name TrinityRail in two main segments: railcar leasing and management services, which owns railcars and provides fleet management and administration services; rail products, which builds, sells, and modifies freight and tank railcars and their components; and all other, which sells highway products such as guardrail and other highway barriers. Customers include railroads, leasing companies, and shipping companies in agriculture, construction, consumer products, energy, and chemicals.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.